论文部分内容阅读
目的:探讨母亲甲状腺功能亢进症(甲亢)对新生儿胎龄、体质量及甲状腺功能的影响。方法:选择我院收治的90例妊娠期甲亢患者,根据其治疗方式分为试验组1和试验组2,每组45例,其中试验组1采用非抗甲状腺药物治疗,试验组2采用抗甲状腺药物治疗,比较两组患者的治疗效果。同时选取45例健康产妇,设为对照组,比较三组产妇的新生儿体质量、胎龄和性别。结果:三组新生儿体质量两两比较差异均有统计学意义(P<0.05),试验组1<试验组2<对照组,性别及胎龄比较差异无统计学意义(P>0.05)。不良妊娠结局的发生率试验组1为42.22%(19/45),试验组2为8.89%(4/45),对照组为2.22%(1/45),试验组1的不良妊娠结局发生率均明显高于试验组2及正常对照组(P<0.05)。三组TSH、FT3、FT4水平两两比较差异均有统计学意义(P<0.05),试验组1>试验组2>对照组。结论:妊娠期甲亢应用抗甲状腺药物治疗后能够改善新生儿的甲状腺功能,减少妊娠不良结局。
Objective: To investigate the effect of maternal hyperthyroidism (Hyperthyroidism) on gestational age, body weight and thyroid function in newborns. Methods: Ninety patients with hyperthyroidism during pregnancy were divided into experimental group 1 and experimental group 2 according to their treatment methods, 45 cases in each group, in which experimental group 1 was treated with non-anti-thyroid drug and experimental group 2 was treated with anti-thyroid Drug treatment, the treatment effect of two groups of patients were compared. At the same time, 45 healthy maternal women were selected as the control group, and the body weight, gestational age and gender of the newborns in the three groups were compared. Results: There was a significant difference in the body weight between three groups (P <0.05). There was no significant difference in test group 1 0.05). The incidence of adverse pregnancy outcomes was 42.22% (19/45) in trial group 1, 8.89% (4/45) in trial group 2, and 2.22% (1/45) in control group. The incidence of adverse pregnancy outcomes in trial group 1 Were significantly higher than the experimental group 2 and normal control group (P <0.05). The levels of TSH, FT3 and FT4 in the three groups were significantly different (P <0.05). The experimental group 1> the experimental group 2> the control group. Conclusion: Hyperthyroidism during pregnancy with anti-thyroid drugs can improve neonatal thyroid function and reduce the adverse pregnancy outcome.